Biosimilar infliximab in anti-TNF-naïve IBD patients - 1-year clinical follow-up
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10330480" target="_blank" >RIV/00064165:_____/16:10330480 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/16:10330480 RIV/00064203:_____/16:10330480
Result on the web
<a href="http://www.prolekare.cz/linkout/59897" target="_blank" >http://www.prolekare.cz/linkout/59897</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.14735/amgh2016514" target="_blank" >10.14735/amgh2016514</a>
Alternative languages
Result language
angličtina
Original language name
Biosimilar infliximab in anti-TNF-naïve IBD patients - 1-year clinical follow-up
Original language description
Biosimilar infliximab (IFX) has been approved for the treatment of inflammatory bowel disease (IBD) in the European Union since September 2013. The approval process included extrapolation of clinical data from other indications, namely, rheumatoid arthritis and ankylosing spondylitis. Data from clinical practice are therefore desirable to confirm the efficacy and safety of biosimilar IFX in the IBD population. Evidence of the long-term efficiency and safety of maintenance treatment with biosimilar IFX in patients with IBD is sparse. Methods: Data from consecutive patients with Crohn's disease (CD) and ulcerative colitis (UC) who were started on biosimilar IFX between January 2015 and May 2016 at our center were analyzed. Patients were assessed as non-responders, partial responders, or complete responders based on clinical, endoscopic, and laboratory parameters. Besides clinical and endoscopic evaluation, C reactive protein levels, fecal calprotectin levels, blood counts, IFX trough levels, and anti-IFX antibody levels were measured. All adverse events were recorded. Final analysis was performed at week 54.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Gastroenterologie a hepatologie
ISSN
1804-7874
e-ISSN
—
Volume of the periodical
70
Issue of the periodical within the volume
6
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
9
Pages from-to
514-522
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-85012863835